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EB peptideConcerns about the possible use of Variola virus, the causative agent of smallpox, as a weapon for
bioterrorism have led to renewed efforts to identify new antivirals against orthopoxviruses. We identiﬁed a
peptide, EB, which inhibited infection by Vaccinia virus with an EC50 of 15 μM. A control peptide, EBX,
identical in composition to EB but differing in sequence, was inactive (EC50N200 μM), indicating sequence
speciﬁcity. The inhibition was reversed upon removal of the peptide, and EB treatment had no effect on the
physical integrity of virus particles as determined by electron microscopy. Viral adsorption was unaffected by
the presence of EB, and the addition of EB post-entry had no effect on viral titers or on early gene expression.
The addition of EB post-adsorption resulted in the inhibition of β-galactosidase expression from an early viral
promoter with an EC50 of 45 μM. A signiﬁcant reduction in virus entry was detected in the presence of the
peptide when the number of viral cores released into the cytoplasm was quantiﬁed. Electron microscopy
indicated that 88% of the virions remained on the surface of cells in the presence of EB, compared to 37% in
the control (p b0.001). EB also blocked fusion-from-within, suggesting that virus infection is inhibited at the
fusion step. Analysis of EB derivatives suggested that peptide length may be important for the activity of EB.
The EB peptide is, to our knowledge, the ﬁrst known small molecule inhibitor of Vaccinia virus entry.© 2009 Elsevier Inc. All rights reserved.Introduction
In 1980, theWorld Health Organization declared that smallpox had
been eradicated (WHO, 1980). However, recent concerns about the
use of Variola virus as a bioweapon have led to a reevaluation of the
methods available to control an outbreak of smallpox or a related
orthopoxvirus. Vaccination against smallpox is currently restricted
because of the risk of adverse side effects (Baggs et al., 2005; Casey
et al., 2005; Fulginiti et al., 2003), due in part to the higher percentage
of ﬁrst-time vaccinees, an increase in the number of individuals with
compromised immune systems, and contraindications for those with
heart disease (Baggs et al., 2005; Rotz et al., 2001; Schwartz and
Lebwohl, 2005). Possible side effects of vaccination range in severity
from mild fever and rash to keratitis, systemic infection, encephalitis,
myocarditis and death (Centers for Disease Control, 2003a,b; Baggs et
al., 2005; Casey et al., 2005; Garde, Harper, and Fairchok, 2004; Kim et
al., 2005; Schwartz and Lebwohl, 2005). The risks associated with
vaccination, and the potential for deliberate release of Variola virus,
have led to renewed efforts to identify novel compounds with activity
against poxviruses for potential therapeutic use.ology and Visual Sciences,
Health, 6630 Medical Sciences
A. Fax: +1 608 262 0479.
ll rights reserved.Recently, several compounds have been identiﬁed that inhibit
various steps in poxvirus infection, including virion morphogenesis
(Byrd et al., 2004; Yang et al., 2005) and DNA synthesis (Baker, Bray,
and Huggins, 2003; Buller et al., 2004; Magee, Hostetler, and Evans,
2005; Prichard et al., 2006; Yang and Schneller, 2005). Cidofovir
diphosphate (CDV) inhibits poxvirus infection in vitro and in vivo and
is approved for those with adverse vaccination reactions (Baker, Bray,
and Huggins, 2003; Buller et al., 2004; Kern, 2003; Magee, Hostetler,
and Evans, 2005; Neyts and Clercq, 2003; Smee and Sidwell, 2003).
However, CDV is highly nephrotoxic, thus there is a need to identify
additional compounds with activity against poxviruses.
Here, we describe the antiviral activity of EB, a novel peptide
inhibitor of Vaccinia virus (VACV), the prototypic poxvirus. EB consists
of the 16 amino acid signal sequence of the human ﬁbroblast growth
factor 4 protein (Lin et al., 1995) with an additional 4 amino acid
solubility tag (RRKK) at the amino terminal end. EB is one of a class of
cell penetrating peptides (CPPs), including those derived from the HIV
tat protein (Frankel and Pabo, 1988), poly-arginine peptides (Nakase
et al., 2004; Richard et al., 2003) and the Drosophila antennapedia
homeobox protein (Joliot et al., 1991), that can facilitate the uptake of
covalently attached moieties into cells (Lin et al., 1995). CPPs are
increasingly being investigated as tools for delivering proteins, DNA,
and other cargoes of interest into the cytoplasm or nuclei of cells both
in vitro and in vivo (for a recent review, see (Gupta, Levchenko, and
Torchilin, 2005).
Table 1
Antiviral properties of peptides used in this study.
Peptide Sequence EC50 (μM) CC50 (μM)d
Comprehensivea Pretreated cellsb Post-adsorptionc
EB RRKKAAVALLPAVLLALLAP 15 63 45 N 100
EBX RRKKLAALPLVLAAPLAVLA 150 n.d. n.d. N 100
n.d. = not done.
a HeLa cells were infected with peptide-treated virus for 3 days prior to harvesting. Peptide was present continuously during the infection. Viral titers were determined by plaque
assay.
b HeLa cells were treated with peptide for 1 h prior to infection with the recombinant virus vMJ343. After 3 h incubation at 37 °C, the infected cells were lysed and the
β-galactosidase activity was measured.
c HeLa cells were infected with the recombinant virus vMJ343 at an m.o.i. of 2 for 1 h at room temperature. Peptide was then added and the samples were shifted to 37 °C for 3 h,
lysed, and the β-galactosidase activity was measured.
d 50% cytotoxic concentration, as reported in (Akkarawongsa et al., 2006).
Fig. 1. High concentrations of virus can overwhelm EB activity. HeLa cells grown in 96-
well plates were infected with increasing concentrations of vMJ343 that had been
pretreated with EB (1.56 μM to 200 μM). Four hours post-infection, the cells were lysed
and β-galactosidase activity was measured. The EC50 value of EB against each
concentration of virus was determined from a plot of peptide concentration versus
β-galactosidase activity (data not shown). The data represent the mean of four
replicates.
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transport of a covalently-linked inhibitor of Herpes simplex virus
type 1 (HSV-1) ribonucleotide reductase into cells; however, EB
alone was shown to be a more potent inhibitor than the conjugated
peptide (Bultmann, Busse, and Brandt, 2001). The EB peptide
exhibited several different activities against HSV-1, including
inactivation of HSV-1 virions and inhibition of HSV-1 entry into
cells, and was thus designated EB for “entry blocker” (Bultmann,
Busse, and Brandt, 2001; unpublished data). A scrambled derivative
of EB, EBX, lacked inhibitory activity against HSV-1 (Bultmann,
Busse, and Brandt, 2001). EB was not cytotoxic to HeLa or Vero cells
at concentrations as high as 100 μM, and displayed no cytotoxic
effects when applied at a concentration of 6.1 mM to mouse corneas
(Akkarawongsa et al., 2006). Subsequent studies have shown that EB
is also effective against inﬂuenza virus, including H5 avian strains
(Jones et al., 2006). We now show that EB also inhibits infection by
VACV via a mechanism or mechanisms that appear to be distinct
from its activity against HSV-1 or inﬂuenza virus.
Results
The antiviral activities of EB and the control peptide EBX (Table 1)
against VACV were initially tested using a comprehensive yield
reduction assay where the peptides were present at all times. Virus
(4×104 pfu/mL) was incubated with increasing concentrations of
peptide for 1 h. The viral inoculumwas then added to HeLa cells, and
the virus yield 3 days p.i. was determined by plaque assay. There was a
dose dependent decrease in virus yield in the presence of EB, with an
EC50 value of 15 μM (Table 1). In contrast, the EC50 for the scrambled
peptide was 150 μM (Table 1), indicating that the antiviral effect was
sequence-speciﬁc.
We previously observed that high concentrations of HSV-1 in
solution could overwhelm the antiviral activity of EB (unpublished
data). To determine whether EC50 was dependent on virus concentra-
tion, increasing concentrations of the vMJ343 strain of virus, which
expresses β-galactosidase from an early promoter (Davison and Moss,
1989), were incubated with up to 200 μM EB and then added to HeLa
cells. Four hours later, β-galactosidase activity was measured. As the
concentration of virus increased, the EC50 of EB increased (Fig. 1),
indicating that the activity of the peptide could be overwhelmed by
excessive amounts of virus.
The EB peptide can penetrate cell membranes when added
exogenously (Lin et al., 1995), suggesting that EB may inhibit an
intracellular step in VACV infection. To test whether EB reduced
infectionwhen added after virus infection had been established, HeLa
cells were infected at an m.o.i. of 2 or 5, and 50 μM EB or 85 μM EB,
respectively, was added at 1 h p.i. The titers of virus from EB-treated
cells were the same as those from untreated cells at all time points
measured, indicating that EB was not able to block an established
VACV infection (Fig. 2). These data suggested that EB was not acting
intracellularly.To determine whether EB treatment inhibited VACV attachment,
virus binding was measured by ELISA. Pretreated vMJ343 was added
to HeLA cells (m.o.i.=2) for 1 h at 4 °C. The cells were ﬁxed and
probed for attached virus using polyclonal anti-VACV antisera. No
signiﬁcant decrease in virus attachment in the presence of high
concentrations of EB was detected (p N0.1, Fig. 3A), indicating that
VACV attachment was not inhibited by EB treatment.
These results were also conﬁrmed by a standard immunoﬂuores-
cence assay for virus adsorption (Law and Smith, 2004). Mock- or EB-
treated virus was spinoculated onto cells and adsorbed for 1 h. The
cells were then ﬁxed and stained for adsorbed virus. The number of
adsorbed virions detected per cell in mock-versus EB-treated samples
was not signiﬁcantly different (p=0.75; Table 2; Figs. 3B–D),
conﬁrming the ELISA results that virus adsorption was not quantita-
tively affected by EB.
The data indicated that EB blocked VACV infection post-adsorption
but prior to the establishment of a productive infection. To determine
if EB acted upstream of early gene expression, HeLa cells were infected
for 3 h with vMJ343 that had been mock-treated or incubated with
25 μM or 100 μM EB and then assayed for β-galactosidase activity.
Samples treated with 25 μM EB exhibited 80% less β-galactosidase
activity than mock-treated samples, while β-galactosidase activity in
samples treated with 100 μM EB were indistinguishable from
background (Fig. 4). These data are consistent with the hypothesis
that EB blocked VACV infection at a step prior to early gene expression.
To conﬁrm that EB inhibited VACV entry, the number of VACV cores
released into the cytoplasm was quantitated by immunoﬂuorescence.
Mock-treated or EB-treated VACV (1×104 pfu) was spinoculated onto
Fig. 2. EB is not active when added post-infection. Cells were infected at an m.o.i. of 2
(circles) or 5 (triangles) for 1 h with WR, rinsed once with PBS, and then media only
(ﬁlled symbols) or media containing 50 or 85 μM EB (EC50 for m.o.i.=2 and m.o.i.=5,
respectively; open symbols) was added. Infected cells were harvested at the indicated
times post-addition of EB. All samples were titered in triplicate, with the data
representing the means and standard deviations of the means.
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being ﬁxed and stained for both adsorbed virus and viral cores.
Cycloheximidewas present during the infection to prevent dissolution
of any cores released into the cytoplasm. In the absence of EB there
was an average of 2.74 cores visible per cell. When EB was present, the
number of cores detected dropped signiﬁcantly to 0.1 cores per cell
(p b0.0001; Table 2; Fig. 5). Similar results were obtained when virus
was allowed to adsorb passively to cells (data not shown), thus
spinoculation did not affect the ability of EB to inhibit VACV infection.
These results are consistent with EB inhibiting VACV entry.
As further conﬁrmation that EB inhibited VACV entry, cells were
exposed to VACV alone or to VACV with 50 μM EB for 1 h at 37 °C, thin
sectioned, and the location of virions determined by TEM. Horizontal
and vertical cross-sections were scored for the number of virus
particles attached to cell surfaces (attached, Fig. 6A), the number of
cores visible in the cytoplasm (entered, Fig. 6B), and the number of
virus particles that appeared to be associated with vesicles in the cells
(vesicles, Fig. 6C). The quantitative data are shown in Table 3. The
percentage of virus particles that were attached to cell surfaces was
signiﬁcantly higher in EB-treated samples than in mock-treated
samples (88% vs. 37%, pb0.001), while the percentage of cores visible
in the cytoplasm of the EB-treated samples was signiﬁcantly lower
than in mock-treated samples (0% vs. 42%, pb0.001). The percentage
of virus particles that appeared to be associated with vesicles was not
signiﬁcantly different between the two treatments (12% in EB treated
vs. 21% in untreated, pN0.05). These data conﬁrm that EB blocked
VACV entry.
To determine whether EB inhibits VACV entry primarily through
interactions with the virus or with the cell surface, the EC50 s of EB
when added prior to VACV adsorption, after VACV adsorption, and
simultaneous with VACV adsorption were directly compared. HeLa
cells were chilled to 4 °C and exposed ﬁrst to peptide and then VACV,Fig. 3. EB does not block VACV adsorption. (A) EB does not block VACV adsorption as
measured by ELISA. Chilled HeLa cells were exposed to EB-treated vMJ343 at anm.o.i. of
2 for 1 h at 4 °C, ﬁxed, and probed for attached virus using polyclonal anti-VACV antisera
and an HRP-conjugated secondary. The plates were developed using the SigmaFAST™
OPD kit and read at 490 nm. Data are the means and standard deviations of three
replicates and are representative of two independent runs. (B–D) EB does not block
VACV adsorption as measured by immunoﬂuorescence microscopy. HeLa cells grown
on glass coverslips were mock infected (B) or infected with mock-treated WR (C) or
virus treated with 50 μM EB (D) for 1 h. Cells were then ﬁxed, and stained for adsorbed
virus with polyclonal antiserum (green). Nuclei were stained with Hoechst 33348. Fifty
cells per condition were scored for the number of adsorbed virions detected (see
Table 2). Arrows denote attached virions [scale bars=20 μm].to VACV and then peptide, or to media and then EB-treated VACV. The
infected cells were then shifted to 37 °C for 4 h before β-galactosidase
activity was measured. The β-galactosidase activity was compared to
that observed in cells infected with untreated VACV. The EC50 for EB
Table 2
Effect of EB on VACV adsorption and entry as determined by IFA.
Sample Adsorbeda Enteredb
No peptide control 11.12 2.74
50 μM EB peptide 10.62c 0.1d
a Average number of virions detected on the cell surface.
b Average number of cores detected in the cytoplasm.
c p=0.75 compared to control.
d pb0.0001 compared to control.
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virus was approximately 45 μM, while the EC50 for EB when used to
pretreat the cells was approximately 170 μM (Fig. 7A). These data
indicate that the EB inhibits VACV entry primarily via interactions
between the peptide and the virus at low concentrations of peptide,
while interactions between EB and the cell surface contribute to the
inhibition of VACV at higher concentrations of peptide.
EB irreversibly inactivates HSV-1 (Bultmann, Busse, and Brandt,
2001). To determine whether the antiviral activity of EB against VACV
was due to the peptide irreversibly inactivating VACV, 1×106 pfu of
virus were incubated for 1 h with increasing concentrations of EB in a
ﬁnal volume of 1 mL. The samples were dialyzed and the recovered
virus was titered by plaque assay on HeLa cells. The infectivity of EB-
treated samples was fully restored regardless of the concentration of
EB used (Fig. 7B). Electron microscopy of virus particles treated with
EB showed they were morphologically identical to mock-treated
particles (data not shown). These data indicate that the inhibition of
VACV by EB was reversible and suggested that EB does not grossly
disrupt the integrity of VACV particles.
Successful fusion of the viral envelope and the host cell membrane
has frequently been associated with the ability of VACV to induce cell–
cell fusion fromwithin and fromwithout upon treatment with low pH
(Brown, Senkevich, and Moss, 2006; Gong, Lai, and Esteban, 1990;
Izmailyan et al., 2006; Moss, 2006; Ojeda et al., 2006a, 2006b;
Senkevich and Moss, 2005; Senkevich, Ward, and Moss, 2004;
Townsley, Senkevich, and Moss, 2005a; Townsley, Senkevich, and
Moss, 2005b). The very high m.o.i. used for the fusion-from-without
assay required concentrations of EB approaching toxicity and there-
fore was not done. To determine if EB could inhibit fusion-from-
within, HeLa cells infected at anm.o.i. of 5 for 24 h were brieﬂy treated
with PBS with a pH of 7 or 5. The solution was then neutralized, and
the cells were re-fed either with normal media or media supplemen-
ted with 150 μM EB. Three hours later, the cells were ﬁxed inFig. 4. EB blocks infection before early viral protein synthesis. The vMJ343 virus was
mock-treated or treatedwith EB at the indicated concentrations for 1 h at 37 °C and then
used to infect HeLA cells. The cells were lysed 3 h p.i., and β-galactosidase activity was
measured by ELISA at 570 nm. Cycloheximide (300 μg/mL) was added to one set of
samples as a control for background β-galactosidase activity, and the signal was
subtracted from the test samples. Data represent the mean±standard deviation from
three samples.
Fig. 5. EB blocks core release into the cytoplasm. HeLA cells grown on coverslips were
mock infected (A) or infected with mock-treatedWR (B) or virus treated with 50 μM EB
(C) for 1 h in media containing 300 μg/mL cycloheximide. Cells were then ﬁxed,
permeabilized with 0.1% Triton-X and stained for virus cores using polyclonal antisera
(red). Nuclei were stained with Hoechst 33348. Fifty cells per conditionwere scored for
the number of viral cores detected (see Table 2). Arrows denote representative viral
cores [scale bars=20 μm].paraformaldehyde and visualized. Infected cells treated with low pH
showed considerable syncytia formation compared to infected cells
treated at a neutral pH (Fig. 8A). Infected cells treated with EB,
however, showed little sign of syncytia formation after either pH
treatment, indicating that EB inhibited cell–cell fusion (Fig. 8A). The
combination of the low-pH treatment and subsequent EB exposure
was not toxic to the cells (Fig. 8B). These data suggest that EB blocks
VACV entry by inhibiting fusion between the virus envelope and the
cell membrane.
Structural analysis of EB
To map the regions of EB crucial to its activity, we screened a
library of sequentially-truncated EB derivatives for the loss of anti-
Fig. 6. EB blocks VACV entry into cells. HeLa cells grown on glass coverslips were infected with mock-treated vMJ343 (m.o.i. 100) or virus pretreated with 50 μM EB for 1 h at 37 °C.
Horizontal and vertical sections of the cells were viewed by TEM, and an equal number of virus particles frommock- and EB-treated samples were counted and scored for location. (A)
Representative sample of virus adsorbed to the surface of the cells (Adsorbed). (B) Representative sample of a virus core visible in the cytoplasm (Entered). (C) Representative
sample of a virion contained within a vesicle (Vesicles). Arrows indicate virus cores; arrowhead indicates vesicle membranes.
Table 3
Location of Vaccinia virus particles as determined by EM.
Sample Adsorbeda (%) Enteredb (%) Vesiclesc (%)
No peptide 37 42 21
50 μM EB peptide 88d 0e 12f
a Virions on cell surface.
b Cores in cytoplasm.
c Cores in vesicles.
d pb0.001 compared to control.
e pb0.001 compared to control.
f pN0.05 compared to control.
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peptide for 1 h at a concentration of 100 μM, and then 5×104 pfu of
treated virus were added to conﬂuent HeLa cells for 3 h at 37 °C. The
supernatants were then removed, the monolayers were lysed, and the
substrate was added. Beginning after the RRKK solubility tag, up to 3
residues could be removed without signiﬁcantly reducing activity
(compare EB4- to EB5-, Table 4). Up to 3 residues could be deleted
from the carboxy terminus without reducing the activity (compare
EB-2 and EB-3, Table 4). Note that when deleting from either direction,
antiviral activity was lost when the ﬁrst leucine encountered was
removed. These results suggested that the length of the peptide and
perhaps the presence of the leucine pairs at positions 9–10 and 17–18
may be important for the activity of EB.
To further characterize the role of the various residues in the
antiviral activity of EB, peptide derivatives with alanine, lysine or
glutamic acid substitutions for the individual leucines were screened
(Table 5). Substituting alanine for any of the six leucines had no
signiﬁcant effect on the activity of the peptide, suggesting that
multiple leucine residues may contribute to the antiviral effect.
Substituting lysine for the leucine at position 9 signiﬁcantly reduced
activity (D2; Table 5), but single lysine substitutions for the leucines at
the other positions had no effect on antiviral activity, indicating that
single positive charges can be tolerated at positions 10, 14, 15, 17 and
18 but not at position 9. Single glutamic acid substitutions at positions
9,10,14,17 and 18 signiﬁcantly reduced peptide activity (E2, E1, B7, B4,
B3; Table 5), indicating that negative charges at these positions
adversely affect the ability of the peptide to inhibit VACV activity.
Discussion
Concerns about the deliberate release of Variola virus have
renewed interest in the development of antiviral drugs effective
against orthopoxviruses. Here we describe the anti-VACV activity ofa novel antiviral peptide, denoted EB. The EB peptide blocked VACV
infection with an EC50 of 15 μM in a sequence-speciﬁc manner. The
EB peptide was not virucidal and did not interfere with VACV
attachment; rather, EB blocked the entry of VACV into cells. Addition
of EB after low-pH treatment of infected cells blocked fusion-from-
within, supporting the conclusion that EB inhibited virus fusion.
Pretreatment of cells with EB also resulted in resistance to infection
but with a higher EC50. Thus the antiviral effect could be due to EB
binding to the virus, the cell or both. Further studies will be needed
to determine the target or targets of EB. To the best of our
knowledge, the EB peptide is the ﬁrst known non-antibody inhibitor
of poxvirus entry.
Several lines of evidence support the claim that EB inhibits VACV
entry. First, quantiﬁcation of the number of VACV cores released into
the cytoplasm of infected cells by immunoﬂuorescence microscopy
showed that treatment of the virus with 50 μM EB prior to infection
reduced the number of cores detected by 85% (Fig. 5). Second, the TEM
data showed that signiﬁcantly fewer virus cores were detected in the
cytoplasm of cells when EB was present than in samples with mock-
treated virus (Fig. 6D). Third, treatment with EB led to a reduction in
Fig. 7. EB interacts reversibly with virions to inhibit entry. (A) EB interactions with
virions, not cells, are responsible for VACV inhibition at low concentrations of peptide.
Conﬂuent cells were exposed in triplicate to either EB (●), vMJ343 (m.o.i.=1; ○), or
media (▼) for 1 h at 4 °C. Virus (m.o.i.=1;○,▼) or peptide (●) was then added for 1 h
at 4 °C. Cultures were shifted to 37 °C for 4 h, lysed, and β-galactosidase activity was
measured and compared to the signal present in cells infected with virus in the absence
of EB. Data are the means and standard deviations of triplicate infections; experiment is
representative of three independent trials. Dashed line indicates 50% of the virus-only
control. (B) EB inhibition is reversible by dialysis. VACV (WR; 1×106 pfu/mL) was
incubated with increasing concentrations of EB for 1 h at 37 °C, then dialyzed overnight
at 4 °C using Slide-a-lyzer dialysis cassettes. Samples were then titered in triplicate and
compared to the titer of mock-treated, dialyzed virus (0 μM EB). The bars represent the
standard deviations of the means.
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pretreated with the peptide (Fig. 4) or when the peptide was added
post-adsorption but prior to initiation of entry (Fig. 7A). Additionally,
EB was able to inhibit fusion-from-within in HeLa cells (Fig. 8),
although fusion-from-without was not tested as the concentration of
virus necessary for the assay (∼108 pfu/mL) would overwhelm the
ability of the peptide to inhibit infection and the concentration for
peptide needed for an effect would be toxic to the cells (Fig. 1). When
considered together with the observation that EB did not inhibit
adsorption (Fig. 3), these results indicate that the EB peptide blocks
VACV entry into cells, likely by inhibiting fusion between the virus
envelope and the cell membrane.
Analysis of VACV entry both directly, through EM analysis, and
indirectly, via the analysis of the effects of endosomal inhibitors and
weak bases on infection, currently suggests that VACV is capable of
entering cells by fusion at the surface of the cell (Armstrong, Metz,
and Young, 1973; Carter et al., 2005; Chang and Metz, 1976; Doms,
Blumenthal, and Moss, 1990; Janeczko, Rodriguez, and Esteban, 1987;
Law et al., 2006; Vanderplasschen, Hollinshead, and Smith, 1998),
macropinocytosis (Mercer and Helenius, 2008), or via an endosomal
pathway (Dales, 1963; Dales and Kajioka, 1964; Payne and Norrby,
1978; Vanderplasschen, Hollinshead, and Smith, 1998). Entry by the
WR strain of virus is inhibited by endosomal inhibitors and thus
appears to enter mostly via endocytosis (Townsley et al., 2006;
Vanderplasschen, Hollinshead, and Smith, 1998). Therefore, it was
possible that EB could have been disrupting VACV entry by blocking
the escape of virus from endocytic vesicles. However, this is unlikely
as we observed no signiﬁcant difference between the percentage of
virus particles that appeared to be associated with vesicles in cells
infected with EB-treated or mock-treated virus by TEM (Fig. 6C).
Determining whether EB blocks VACV entry at the cell surface,
prevents the release of virus from endosomes, or both will require
further study.
Vaccinia virus infection results in the production of two
immunologically distinct infectious particles: the single-enveloped
mature virus (MV) and the double-enveloped extracellular virus
(EV) (Moss, 2006). The EV particle is composed of an MV particle
surrounded by an additional lipid bilayer envelope. EM analysis of EV
entry has suggested that the outer envelope of the particle is shed at
the surface of the cell in a nonfusogenic, ligand-dependent manner,
leaving the interior MV particle free to enter the cell (Law et al.,
2006). EV particles are released in low quantity by VACV strain WR
grown in HeLa cells (Payne, 1979) and are disrupted by repeated
freezing; thus, the majority of the virus particles used in our study
were MVs. Further studies will be needed to determine if EB blocks
infection by EVs.
Most of these assays were performed using virus that was
pretreated with EB. Previous studies have shown that exposure of
cells to EB protects them from infection with HSV-1 (manuscript in
preparation), so it was possible that the antiviral activity we observed
could have been the result of interactions between EB and the cells.
The EB peptide was able to reduce infection by VACV when used to
pretreat cells prior to infection, however, at low concentrations of EB
interactions between the peptide and the virus were more important
to the inhibition of VACV infection thanwere interactions between the
peptide and the cells (Fig. 7A). In terms of therapeutic uses, at drug
concentrations that would likely be used, both activities would be
occurring.
Our data indicate that removing 4 residues from the N-terminus or
3 residues from the C-terminus of EB had little effect on peptide
activity (compare Table 4; EB-2 to EB-3 and EB4- to EB5-) but larger
deletions reduced activity. These data suggest peptide length may be
important. Derivatives of EB containing single amino acid substitu-
tions for the leucine residues lost activity when the substituting
residuewas negatively charged (Table 5; E2, E1, B7, B4, B3), suggesting
that a negative charge at these positions are detrimental. In contrast,single positive charges, with the exception of position 9, did not
signiﬁcantly reduce activity. The presence of 3 leucine pairs is a
distinctive feature of the EB peptide and was potentially important for
the antiviral activity. However, derivatives of EB containing alanine
substitutions for single leucines did not affect activity (Table 5; F2, F1,
C7, C6, C4, C3), thus leucine pairs are not required. Previously it was
shown that the leucine content of signal peptides was critical for
interactions with the signal recognition particle as increasing the
alanine: leucine ratio negatively affected function (Doud, Chou, and
Kendall, 1993; Hatsuzawa, Tagaya, and Mizushima, 1997; Zanen et al.,
2005). This raises the possibility that total leucine content is
important for the activity of EB, However, EBX has the same leucine
content and is inactive. Our observation that the EBX peptide was
inactive indicates that the sequence is important and raises the
possibility that the spacing of the leucines may play an important role
in the antiviral activity of EB. Further studies will be needed to test
these alternatives. The effects of the single leucine substitutions
cannot be directly compared to the effects of truncation, as the total
length of the peptide remains constant in the substituted derivatives.
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concurrent action of several amino acids.
The EB peptide is derived from the signal sequence of the human
FGF4 protein (Lin et al., 1995). Signal sequences are highly variable
(von Heijne, 1985), and are known to bind the SRP in a methionine-
rich hydrophobic pocket (Lutcke et al., 1992). The hydrophobicity of
this pocket is believed to be crucial for the ability of the SRP to
recognize a broad range of signal sequences independent of their
speciﬁc sequences (Keenan et al., 2001). Similarly, sorting of some
transmembrane proteins to the endosomal–lysosomal system has
been shown to depend on the interaction between dileucine sorting-
signals and hydrophobic pockets (Misra et al., 2002; Shiba et al.,
2002). It is possible that EBmay be interacting with a similar pocket in
one or more of the VACV entry-fusion complex proteins, thereby
disrupting complex function. Eleven proteins, A16, A21, A28, F9, G3,
G9, H2, I2, J5, L1, and L5, have been implicated in VACV entry, (Bisht,
Weisberg, and Moss, 2008; Brown, Senkevich, and Moss, 2006;
Izmailyan et al., 2006; Nichols et al., 2008; Ojeda et al., 2006a, 2006b;
Senkevich and Moss, 2005; Senkevich et al., 2005; Senkevich, Ward,
and Moss, 2004; Townsley, Senkevich, and Moss, 2005a; Townsley,
Senkevich, and Moss, 2005b), and A17 and A27 have been implicated
in cell–cell fusion (Kochan et al., 2008). Identiﬁcation of the viral
protein or proteins that bind to EB will be important in describing the
mechanism of inhibition and such studies are underway.
The EB peptide has previously been shown to have antiviral
activity against both HSV-1 and inﬂuenza virus (Bultmann, Busse, and
Brandt, 2001; Jones et al., 2006), and we can now add VACV to the list
of viruses inhibited by EB. However, the mechanism by which EB
inhibits these viruses appears to be different for each virus. The EB
peptide was shown to block HSV-1 entry by irreversibly inactivating
virus particles (Bultmann, Busse, and Brandt, 2001), whereas EB did
not irreversibly inactivate VACV. EB did not irreversibly inactivate
inﬂuenza; instead, EB blocked virus adsorption by binding speciﬁcally
to the viral hemagglutinin protein (Jones et al., 2006), which is in
contrast to VACV where adsorption was not blocked.
In summary, we have identiﬁed a novel antiviral peptide, EB, which
inhibits VACV entry with an EC50 of 15 μM. The activity was sequence-
speciﬁc and reversible. The EB peptide was active when used to
pretreat virus, when added after virus adsorption but prior to the
initiation of entry, or when used to pretreat cells, and inhibited fusion
from within. These results indicate that EB inhibits virus–cell fusion.
The EB peptide is, to our knowledge, the ﬁrst identiﬁed non-antibody
inhibitor of VACV entry, and has potential for development in clinical
applications and as a reagent to probe VACV entry.
Materials and methods
Cells and viruses
HeLa cells were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 5% calf serum and 5% fetal
bovine serum. Infections using the wild-type WR strain of Vaccinia
virus or the recombinant vMJ343 strain were performed in DMEM
supplemented with 1% calf serum and 1% fetal bovine serum
(infection media). The recombinant Vaccinia virus vMJ343 expresses
lacZ under the control of an artiﬁcial early promoter (Davison and
Moss, 1989), and was kindly provided by Dr. Bernard Moss
(Laboratory of Viral Diseases, NIAID, Bethesda, MD).Fig. 8. EB blocks fusion-from-within. (A) Conﬂuent HeLa cells in 24-well plates were infecte
adjusted to the indicated pH for 3 min, washed twice with infection media, and incubate
paraformaldehyde and examined for syncytia formation. Arrows denote syncytia. Bars=1
Conﬂuent HeLa cells were treated with PBS (pH 7 or 5), rinsed twice with DMEM+2% FBS, a
(#G3580, Promega Corporation, Madison,WI) in DMEM+2% FBSwith or without the additio
Product formation was measured at 490 nm using an ELX-800 plate reader (Biotek, Winoosk
signal from wells containing CellTiter 96® AQueous One Solution alone.To propagate virus, conﬂuent HeLa cells were infected at a
multiplicity of infection (m.o.i.) of 0.1. Three days post-infection,
supernatants and cells were harvested. The cells were frozen and
thawed three times and the nuclei were pelleted by centrifugation.
The supernatants were combined and layered onto a cushion of 36%
sucrose and centrifuged at 20,000 ×g for 80 min in an SW28 rotor
(Beckman, Fullerton, CA). The pelleted virus was then resuspended
and stored in 10 mM Tris–HCl, pH 9.0 at −80 °C until use. To purify
virions for attachment assays, viruses were centrifuged in a conti-
nuous sucrose gradient (25%–40% in 10 mM Tris–HCl, pH 9.0) at
19,000 ×g for 50 min using an SW41 rotor (Beckman, Fullerton, CA).
The resulting band of virus was then removed and stored at −80 °C
until use.
Peptides
Synthesis and analysis of the EB and EBX peptides were done at
the Biotechnology Center of the University of Wisconsin-Madison as
has previously been described (Bultmann and Brandt, 2002;
Bultmann, Busse, and Brandt, 2001); (Bultmann, Teuton, and
Brandt, 2007). Brieﬂy, synthesis was carried out at a 25 pmol
scale using an automated synthesizer (Applied Biosystems model
432A). The cleaved peptides were precipitated with cold t-
butylmethylether, and their relative mass was conﬁrmed by
electrospray ionization mass spectroscopy. The purity of the peptides
was determined by HPLC, and peptide concentrations in solution
were determined by absorbance readings at 215 and 225 nm. The
peptide library of EB derivatives was synthesized by EZBiolab Inc.
(Westﬁeld, IN). The sequences of the tested peptides are given in
Tables 4 and 5.
Comprehensive inhibition assay
To determine the EC50 of the peptides when they were present at
all times during the infection, 4×104 pfu/mL of virus were incubated
with increasing concentrations of peptide ranging from 1.56 μM to
200 μM for 1 h at 37 °C in a ﬁnal volume of 1.2 mL. Conﬂuent HeLa
cells grown in 24 well plates were then infected in triplicate with the
virus/peptide mixture at an m.o.i. of 0.1 for 1 h at 37 °C before
additional media and peptide were added to bring the ﬁnal volume
of each well to 1 mL. Peptide was present continuously during the
infection. Three days post-infection the samples were harvested,
frozen and thawed 3 times, and yields were determined by plaque
assay on HeLa cells.
To test the dependence of the EC50 on virus concentration, HeLa
cells were plated at a density of 1×104 cells/well of a 96-well plate
and grown to conﬂuency. Peptide (1.56 μM to 200 μM) was incubated
with 5×104, 5×105, 5×106 or 5×107 pfu/mL of vMJ343 for 1 h at
37 °C. Ten microliters of the mixture was then plated in quadruplicate
on HeLa cell monolayers and incubated for 1 h at 37 °C before the cells
were re-fed with infectionmedia. After an additional 3 h incubation at
37 °C, an equal volume of lysis buffer (0.5% NP-40, 2 mMMgCl2 in PBS)
was added to each well, and the samples were incubated at room
temperature for 10 min. Substrate was added (CPR-gal; Chlorophenol
red-β-D-galactopyranoside, #10884308001, Roche Applied Science,
IN), and the initial rate of product formationwas measured at 570 nm
using an ELX-800 plate reader (Biotek, Winooski, VT) in the linear
range.d at an m.o.i. of 5 with WR and incubated for 24 h. The cells were then exposed to PBS
d 3 h with infection media with or without 150 μM EB. The samples were ﬁxed with
00 μm. (B) EB is not toxic to cells when added immediately after low-pH treatments.
nd then incubated for 1 h at 37 °C in a 1:5 dilution of CellTiter 96® AQueous One Solution
n of 150 μMEB. The reactionwas halted by the addition of 25 μL of 2.5% NP-40 in DMEM.
i, VT). Data represent 6 independent samples per condition, and were normalized to the
Table 4
Effect of truncation on EB activity against Vacciniaa.
a Highlighted derivatives retained levels of antiviral activity not signiﬁcantly different
(p N0.05) by one-component ANOVA from EB.
b Average mOD/min of two separate trials.
c High variability between trials prevented the loss of activity from being statistically
signiﬁcant.
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HeLa cells grown to conﬂuency in 24-well plates were infected
with virus at an m.o.i. of 2 or an m.o.i. of 5 for 1 h. One set of wells was
then harvested (T=0), and the supernatants were removed from the
remaining wells. One milliliter of infection media alone or infection
media with 50 μM EB (EC50 for m.o.i. of 2) or 85 μM EB (EC50 for m.o.i.
or 5) was added to the remaining wells, and cells were harvested at 1,
6, 12, 24 and 48 h after the addition of peptide. Each sample was
titered in triplicate on HeLa cells.
Virus attachment ELISA
The recombinant virus vMJ343 (1×106 pfu) was incubated with
increasing concentrations of peptide for 1 h at 37 °C and chilled. The
virus solution was plated on chilled HeLa cells in a 96-well plate
(50 μL per well, m.o.i.=2) for 1 h at 4 °C, washed with chilled PBS,
and ﬁxed at RT for 30 min in 4% paraformalde and stored overnight
in PBS at 4 °C. The plate was then blocked for 30 min in 3% BSA,
probed for 1 h with a 1:500 dilution of rabbit anti-VACV antibody
(#8101, Virostat, Portland, ME) for 1 h at 37 °C in a humid chamber,
and rinsed 3 × with PBS. Secondary antibody (HRP goat anti-rabbit,
#sc2030, Santa Cruz Biotechnology, Santa Cruz, CA) was added at a
1:1000 dilution for 1 h at 37 °C in a humid chamber. The wells were
rinsed 3 × with PBS and developed using the SigmaFAST™ OPD kit
(#P9187, Sigma Aldrich, St. Louis, MO) according to the manufac-
turer's instructions. The plate was read at 490 nm using an ELX-800
plate reader (Biotek, Winooski, VT).
Detection of early gene expression
Conﬂuent HeLa cells grown in 96-well plates were infected with
mock-treated vMJ343 (8.75×105 pfu) or virus pretreated with
25 μM or 100 μM EB in a ﬁnal volume of 100 μL for 1 h. After
incubation at 37 °C for 3 h, the supernatants were removed and the
cells were lysed and developed as for the comprehensive inhibition
assay. A control for virus-associated β-galactosidase was run in the
presence of 300 μg/mL cycloheximide to inhibit β-galactosidase
expression and the signal was subtracted from the cycloheximide-
free samples.
Post-attachment assay
HeLa cells were grown to conﬂuency in 96-well plates and infected
with vMJ343 at an m.o.i. of 10 in a volume of 50 μL at room
temperature for 1 h. Concentrations of EB ranging from no peptide
(mock-treated control) to 200 μM were then added in a ﬁnal volume
of 100 μL per well. The samples were then incubated at 37 °C for 3 h
prior to the measurement of β-galactosidase activity as described
above.
Fluorescent microscopy
The entry assay was modiﬁed from the protocol described by Law
and Smith (2004). Brieﬂy, HeLa cells were grown to conﬂuency on
glass coverslips. VACV (1×104 pfu/mL) was incubated with 50 μM EB
or EBX and 300 μg/mL cycloheximide for 1 h at 37 °C in a total volume
of 500 μL. The mixture was then plated onto the cells, and the cells
were spinoculated at 650 ×g for 1 h at 4 °C using a Beckman T6-J
centrifuge. The samples were transferred to 37 °C for one hour, then
ﬁxed with 10% formaldehyde in PBS for 20 min and rinsed 3 times
with PBS before being stored overnight at 37 °C in PBS. The samples
were then washed three times for 5 min in 100 mM glycine and then
blocked for 30 min with 10% FBS in PBS. The coverslips were probed
for 1 h at 37 °C with polyclonal goat anti-VACV antisera (1:250
dilution; # V0500-01, USBiologicals, Swampscott, MA), rinsed 3 timeswith PBS, and stained with 1:200 IgG Alexa Fluor 488 donkey anti-
goat (A11055, Molecular Probes, CA) for 1 h at 37 °C. After rinsing 3
times with PBS, the cells were permeabilized for 5 min with 0.1%
Triton-X in PBS, washed 3 times in PBS, and blocked an additional
30 min. Virus cores within the cytoplasm were probed with 1:500
polyclonal rabbit anti-core serum (gift of G. Grifﬁths, EMBL, Heidel-
berg, Germany) and stained with 1:200 IgG Alexa Fluor 594 goat anti-
rabbit (#A11012, Molecular Probes, CA). The cells were rinsed once in
PBS, incubated for 5 min in PBS+1 ng/mL Hoechst 33342 (#H1399,
Molecular Probes, CA), and rinsed a ﬁnal time before the coverslips
were mounted on slides with ImmunoMount (ThermoShandon,
Pittsburgh, PA). Coverslips were viewed with an Axioplan 2
ﬂuorescent microscope (Zeiss, Göttingen, Germany), photographed,
and the number of attached virus and viral cores was counted for 50
cells. All images using the same ﬁlter were taken using the same
exposure.
Electron microscopy (EM)
A total of 1×107 pfu/mL of gradient-puriﬁed vMJ343 were
incubated at 37 °C in media with or without 50 μM EB and
supplemented with 300 μg/mL cycloheximide. HeLa cells grown to
conﬂuency on 10 mm glass coverslips were then infected at a
multiplicity of infection of 100 for 1 h at 37 °C. Samples were ﬁxed in
2.5% glutaraldehyde, 2.0% paraformaldehyde in 0.1 M sodium
cacodylate buffer, pH 7.4 for 1 h at room temperature. The cells
were then post-ﬁxed in 1% osmium tetroxide (OsO4) in the same
buffer for 1 h at room temperature. Following OsO4 post-ﬁxation, the
samples were dehydrated in a graded ethanol series, further
dehydrated in propylene oxide and embedded in Epon. The samples
Table 5
Effect of leucine substitution on EB activity against VACVa.
a Highlighted derivatives displayed signiﬁcantly less activity (p b0.05 by one-
component ANOVA) than EB.
b Bold residues indicate substitutions.
c Average mOD/min of two separate trials.
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cover slips and sectioned using a Reichert-Jung Ultracut-E Ultra-
microtome. After staining with Reynolds lead citrate and 8% uranyl
acetate in 50% ethanol, ultrathin sections were viewed with a Philips
CM120 electron microscope and images were captured with a
MegaView III side-mounted digital camera. Virus particles from ∼30
ﬁelds of view per condition were scored based on whether they were
adsorbed to the cell surface (adsorbed), whether the virus cores had
been released into the cytoplasm (entered), or whether the virus
particles were associated with vesicles within the cytoplasm
(vesicles).
Inactivation of virions
To determine if EB inactivated virions, 1×106 pfu/mL of virus were
incubated with increasing concentrations of peptide ranging from
1.56 μM to 200 μM for 1 h at 37 °C. The virusmixturewas then dialyzed
overnight at 4 °C against 10 mM Tris with 0.1 M NaCl, pH 7.4 (Slide-
A-Lyzer dialysis cassette, #66425, Pierce, Rockford, IL) and titered by
plaque assay on HeLa cells.
Cell pretreatment assay
HeLa cells grown to conﬂuency in 96-well plates were pretreated
in triplicate with 50 μL of peptide (1.5625 μM to 200 μM) in infection
media for 1 h at 37 °C. The mediumwas then removed, and 500 pfu of
vMJ343 were added per well (m.o.i.=0.2). The amount of virus used
fell within the linear range of β-galactosidase signal detected from
cells infected by vMJ343 as determined by standard curve (data not
shown). Infected cells were incubated for 3 h at 37 °C, when the
medium was removed. Lysis buffer (50 μL) was then added, and
β-galactosidase activity was measured as described above.
Determining the contribution of peptide–cell interactions to EB activity
HeLa cells grown in 96-well plateswere chilled to 4 °C and exposed
to EB, infected with vMJ343 (m.o.i.=1), or treated with media for 1 h.
The liquid was then decanted and replaced with vMJ343, EB, or EB-
treated vMJ343 (m.o.i.=1), respectively, for 1 h at 4 °C. Thetemperature was then raised to 37 °C for 4 h. The medium was
removed, lysis buffer was added, and the β-galactosidase activity
measured as described above. Data were normalized to endogenous
β-galactosidase levels in uninfected cells. The EC50 of EB under all
three conditions was determined relative to the β-galactosidase
activity measured in cells infected with mock-treated vMJ343.
Fusion from within
Conﬂuent HeLa cells grown in 24-well plates were infected at anm.
o.i. of 5 for 24 h. The medium was then removed, and the wells
incubated for 3 min at room temperature with PBS adjusted to a pH of
7.0 or 5.0. The wells were then washed twice with media and
incubated at 37 °C for 3 h in media with or without 150 μM EB. The
cells were then ﬁxed in 4% paraformaldehyde in PBS for 30 min and
stored in PBS until viewed with an Axiovert 200 M inverted
microscope (Carl Zeiss, Thornwood, NY). Pictures are representative
of two independent experiments per condition.
To verify that EB was not toxic to cells when added immediately
after the low-pH wash, HeLa cells grown to conﬂuency in a 96-well
plate were treated with PBS adjusted to a pH of 7 or 5 as above, rinsed
twice with DMEM+2% FBS, and then incubated for 1 h at 37 °C in a
1:5 dilution of CellTiter 96® AQueous One Solution (#G3580, Promega
Corporation, Madison, WI) in DMEM+2% FBS with or without the
addition of 150 μM EB (total volume, 100 μL). The reaction was then
halted by the addition of 25 μL of 2.5% NP-40 in DMEM, and product
formationmeasured at 490 nm using an ELX-800 plate reader (Biotek,
Winooski, VT). Data represent 6 independent samples per condition,
and were normalized to the signal fromwells containing CellTiter 96®
AQueous One Solution alone.
Screening of the peptide library
Conﬂuent HeLa cells in 96-well plates were infected for 3 h at 37 °C
with 5×104 pfu/well of vMJ343 that had been pretreated for 1 h with
100 μMof peptide. The supernatants were removed and the cells were
lysed and developed as above. To control for virion-associated
β-galactosidase, one set of samples was run in the presence of
300 μg/mL cycloheximide and the signal was subtracted from the
cycloheximide-free samples.
Statistical analysis
Student's paired t-tests were performed using Microsoft Excel.
One-way ANOVA tests were performed using Sigmaplot 11 (Systat
Software Inc., San Jose, CA).
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